Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 569

1.

Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo.

Jia XQ, Cheng HQ, Li H, Zhu Y, Li YH, Feng ZQ, Zhang JP.

Chin Med J (Engl). 2011 Nov;124(22):3794-9.

2.

Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer.

Zhou Y, Zhou N, Fang W, Huo J.

Diagn Pathol. 2010 Sep 16;5:58. doi: 10.1186/1746-1596-5-58.

3.

Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo.

Xiong Z, Lü MH, Fan YH, Cao YL, Hu CJ, Wu YY, Wang SM, Luo G, Fang DC, Li C, Yang SM.

Int J Oncol. 2012 May;40(5):1601-9. doi: 10.3892/ijo.2012.1338.

PMID:
22267022
4.

[The influence of downregulation of ezrin expression by RNA interference on the growth and metastasis of hepatocellular carcinoma: experiment in vitro].

Zhang Y, Hu MY, Chen BH, Wang ZJ, Zha XL, Liu KD.

Zhonghua Yi Xue Za Zhi. 2006 Feb 28;86(8):530-5. Chinese.

PMID:
16681881
5.

High ADAM8 expression is associated with poor prognosis in patients with hepatocellular carcinoma.

Zhang Y, Tan YF, Jiang C, Zhang K, Zha TZ, Zhang M.

Pathol Oncol Res. 2013 Jan;19(1):79-88. doi: 10.1007/s12253-012-9560-6.

PMID:
22965687
6.

A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.

Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR.

Cancer Res. 2001 Sep 1;61(17):6428-36.

7.

ShRNA-targeted COMMD7 suppresses hepatocellular carcinoma growth.

Zheng L, Liang P, Li J, Huang XB, Liu SC, Zhao HZ, Han KQ, Wang Z.

PLoS One. 2012;7(9):e45412. doi: 10.1371/journal.pone.0045412.

8.

Involvement of hepatopoietin Cn in the development of human hepatocellular carcinoma.

Zhu BD, Li XL, Liu Y, Chang J, Liu Y, Zhang DD, Wang Q, Ren J, Cui CP.

Clin Exp Metastasis. 2010 Dec;27(8):571-80. doi: 10.1007/s10585-010-9346-8.

PMID:
20683644
9.

Survivin downregulation by siRNA/cationic liposome complex radiosensitises human hepatoma cells in vitro and in vivo.

Yang W, Sun T, Cao J, Liu F.

Int J Radiat Biol. 2010 Jun;86(6):445-57. doi: 10.3109/09553001003668006.

PMID:
20470195
10.

Tumor-targeted efficiency of shRNA vector harboring chimera hTERT/U6 promoter.

Zhang P, Chen Y, Jiang X, Tu Z, Zou L.

Oncol Rep. 2010 May;23(5):1309-16.

PMID:
20372845
11.

Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro.

Wu QF, Liu C, Tai MH, Liu D, Lei L, Wang RT, Tian M, Lü Y.

Acta Pharmacol Sin. 2010 Mar;31(3):361-6. doi: 10.1038/aps.2010.4.

12.

[Experimental research of therapeutic effect on hepatocellular carcinoma of targeting SMYD3 gene inhibition by RNA interference].

Xu JY, Chen LB, Xu JY, Yang Z, Xu RH, Wei HY.

Zhonghua Wai Ke Za Zhi. 2006 Apr 1;44(7):481-4. Chinese.

PMID:
16772086
13.

[Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference].

Zhang PH, Tu ZG, Yang MQ, Huang WF, Zou L, Zhou YL.

Ai Zheng. 2004 Jun;23(6):619-25. Chinese.

PMID:
15191658
14.

[Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2].

Xu JY, Chen LB, Xu JY, Yang Z, Wei HY, Xu RH.

Ai Zheng. 2006 May;25(5):526-32. Chinese.

PMID:
16687068
15.
16.

Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma.

Xue X, Gao W, Sun B, Xu Y, Han B, Wang F, Zhang Y, Sun J, Wei J, Lu Z, Zhu Y, Sato Y, Sekido Y, Miao Y, Kondo Y.

Oncogene. 2013 Mar 28;32(13):1724-34. doi: 10.1038/onc.2012.177.

PMID:
22614011
17.

RNA interference against granulin-epithelin precursor prevents hepatocellular carcinoma growth: its application as a therapeutic agent.

Park MY, Park YS, Nam JH.

Int J Oncol. 2011 Oct;39(4):853-61. doi: 10.3892/ijo.2011.1095.

PMID:
21701774
18.

Overexpression of HOXA1 correlates with poor prognosis in patients with hepatocellular carcinoma.

Zha TZ, Hu BS, Yu HF, Tan YF, Zhang Y, Zhang K.

Tumour Biol. 2012 Dec;33(6):2125-34. doi: 10.1007/s13277-012-0472-6.

PMID:
22864671
20.

Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma.

He C, Sun XP, Qiao H, Jiang X, Wang D, Jin X, Dong X, Wang J, Jiang H, Sun X.

Cancer Sci. 2012 Mar;103(3):528-34. doi: 10.1111/j.1349-7006.2011.02177.x.

Items per page

Supplemental Content

Support Center